Healthcare -
Biotechnology - NASDAQ - US
$ 1.345
-15.4 %
$ 86.8 M
Market Cap
-0.78
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Inozyme Pharma, Inc.
| Net Income | -102 M |
| Depreciation & Amortization | 742 K |
| Capital Expenditures | -62 K |
| Stock-Based Compensation | 7.94 M |
| Change in Working Capital | 4.71 M |
| Others | 66 K |
| Free Cash Flow | -92 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2001 | |
|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||
| Net Income | (102.0) | (71.2) | (67.1) | (56.6) | (56.4) | (19.7) | (7.0) | 0 |
| Depreciation & Amortization | 0.7 | 0.8 | 0.7 | 0.7 | 0.2 | 83 K | 26 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0.2 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 7.9 | 7.0 | 7.7 | 7.2 | 2.3 | 0.3 | 0.4 | 0 |
| Other Operating Activities | (3.3) | (4.3) | (1.1) | 0.4 | 18.0 | 71 K | (4.4) | 0 |
| Change in Working Capital | 4.7 | (3.1) | 2.0 | 85 K | (0.1) | 0.6 | 1.4 | 0 |
| Cash From Operations | (91.9) | (70.7) | (57.8) | (48.2) | (36.0) | (18.8) | (9.4) | 0 |
| INVESTING CASH FLOW | ||||||||
| Capital Expenditures | 62 K | (0.3) | (0.4) | (0.4) | (0.6) | (0.1) | (0.3) | 0 |
| Other Items | 67.1 | (53.3) | (5.0) | 43.2 | (116.6) | (8.3) | 9.3 | 0 |
| Cash From Investing Activities | 67.0 | (53.6) | (5.4) | 42.8 | (117.2) | (8.4) | 9.0 | 0 |
| FINANCING CASH FLOW | ||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 40.0 | 4.0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.9 | 0.3 | 12.6 | 0.6 | 33.8 | 23.0 | 31.9 | 0 |
| Cash From Financing Activities | 11.4 | 126.0 | 72.8 | 0.6 | 149.8 | 23.0 | 31.9 | 0 |
| CHANGE IN CASH | ||||||||
| Net Change In Cash | (13.5) | 1.6 | 9.6 | (4.7) | (3.3) | (4.2) | 31.5 | 0 |
| FREE CASH FLOW | ||||||||
| Free Cash Flow | (92.0) | (71.0) | (58.2) | (48.5) | (36.5) | (18.9) | (9.7) | 0 |